Highlights
- •CSF analysis can differentiate CBS-AD from CBS non-AD patients.
- •30% of CBS patients have an underlying AD pathology.
- •Alien hand phenomena are more common in CBS-AD patients.
- •Clinical and imaging features cannot safely differentiate CBS-AD from CBS-nAD.
Abstract
Background
Corticobasal syndrome (CBS) can harbor diverse pathologies, such as corticobasal degeneration
(CBD) and Alzheimer's disease (AD). CSF biochemical analysis in CBS patients can confidently
distinguish between an AD (CBS-AD) and a non-AD (CBS-nAD) pathology.
Objective
We utilized classical CSF biomarkers to make a distinction between the two groups
and examine their clinical, neuropsychological, neuropsychiatric and imaging differences.
Methods
Seventeen patients with a CBS phenotype were included. Detailed clinical history,
and neurological examination data were recorded. A thorough neuropsychological and
neuropsychiatric test battery was performed, including Goldenberg apraxia test. Simple
linear MRI measurements and planimetry data were utilized. CSF biomarkers for AD were
ascertained.
Results
Five of seventeen CBS patients had a CSF AD profile. Patients with a CSF AD profile
(CBS-AD; n = 5) were older and had a greater age at disease onset compared to CBS-nAD.
CBS-AD patients had more frequently alien hand phenomena at examination and greater
hippocampi surface asymmetry at MRI. CBS-nAD patients (n = 12) had lower superior
colliculi width values.
Conclusion
Clinical, neuropsychological and imaging data cannot confidently differentiate CBS-AD
from CBS-nAD patients.
Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Journal of the Neurological SciencesAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Criteria for the diagnosis of corticobasal degeneration.Neurology. 2013; 80: 496-503https://doi.org/10.1212/WNL.0b013e31827f0fd1
- Accuracy of the clinical diagnosis of corticobasal degeneration: a clinicopathologic study.Neurology. 1997; 48: 119-125https://doi.org/10.1212/WNL.48.1.119
- Corticobasal degeneration: neuropathologic and clinical heterogeneity.Neurology. 1997; 48: 959-968https://doi.org/10.1212/WNL.48.4.959
- Pathologic heterogeneity in clinically diagnosed corticobasal degeneration.Neurology. 1999; 53: 795-800https://doi.org/10.1212/WNL.53.4.795
- Is the pathology of corticobasal syndrome predictable in life?.Mov. Disord. 2009; 24: 1593-1599https://doi.org/10.1002/mds.22558
- Does corticobasal degeneration exist? A clinicopathological re-evaluation.Brain. 2010; 133: 2045-2057https://doi.org/10.1093/brain/awq123
- H. Office of Rare Diseases of the National Institutes of, Office of Rare Diseases neuropathologic criteria for corticobasal degeneration.J. Neuropathol. Exp. Neurol. 2002; 61: 935-946
- Imaging correlates of pathology in corticobasal syndrome.Neurology. 2010; 75: 1879-1887https://doi.org/10.1212/WNL.0b013e3181feb2e8
- Clinicopathological correlations in corticobasal degeneration.Ann. Neurol. 2011; 70: 327-340https://doi.org/10.1002/ana.22424
- The diagnosis of dementia due to Alzheimer's disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease.Alzheimers Dement. 2011; https://doi.org/10.1016/j.jalz.2011.03.005
- Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria.Lancet Neurol. 2014; https://doi.org/10.1016/S1474-4422(14)70090-0
- CSF Alzheimer's disease-like pattern in corticobasal syndrome: evidence for a distinct disorder.J. Neurol. Neurosurg. Psychiatry. 2011; 82: 834-838https://doi.org/10.1136/jnnp.2010.221853
- Recommendations to standardize preanalytical confounding factors in Alzheimer's and Parkinson's disease cerebrospinal fluid biomarkers: an update.Biomark. Med. 2012; 6: 419-430https://doi.org/10.2217/bmm.12.46
- CSF biomarkers β-amyloid, tau proteins and a-synuclein in the differential diagnosis of Parkinson-plus syndromes.J. Neurol. Sci. 2017; 382: 91-95https://doi.org/10.1016/j.jns.2017.09.039
- Cerebrospinal fluid biomarkers as a diagnostic tool of the underlying pathology of primary progressive aphasia.J. Alzheimers Dis. 2017; 55: 1453-1461https://doi.org/10.3233/JAD-160494
- Mini Mental State Examination (MMSE): a validation study in Greece.Am. J. Alzheimers. Dis. Other Demen. 2000; 15: 342-345https://doi.org/10.1177/153331750001500604
- Validity and reliablity of the newly translated Hellenic Neuropsychiatric Inventory (H-NPI) applied to Greek outpatients with Alzheimer's disease: a study of disturbing behaviors among referrals to a memory clinic.Int. J. Geriatr. Psychiatry. 2004; 19: 203-208https://doi.org/10.1002/gps.1045
- Pantomime of tool use depends on integrity of left inferior frontal cortex.Cereb. Cortex. 2007; 17: 2769-2776https://doi.org/10.1093/cercor/bhm004
- Defective pantomime of object use in left brain damage: apraxia or asymbolia?.Neuropsychologia. 2003; 41: 1565-1573https://doi.org/10.1016/S0028-3932(03)00120-9
- Clinical significance of lobar atrophy in frontotemporal dementia: application of an MRI visual rating scale.Dement. Geriatr. Cogn. Disord. 2007; 23: 334-342https://doi.org/10.1159/000100973
- Temporal lobe rating scale: application to Alzheimer's disease and frontotemporal dementia.J. Neurol. Neurosurg. Psychiatry. 2001; 70: 165-173https://doi.org/10.1136/jnnp.70.2.165
- Visual assessment of posterior atrophy development of a MRI rating scale.Eur. Radiol. 2011; 21: 2618-2625https://doi.org/10.1007/s00330-011-2205-4
- Atrophy of medial temporal lobes on MRI in “probable” Alzheimer's disease and normal ageing: diagnostic value and neuropsychological correlates.J. Neurol. Neurosurg. Psychiatry. 1992; 55: 967-972
- Simple linear brainstem MRI measurements in the differential diagnosis of progressive supranuclear palsy from the parkinsonian variant of multiple system atrophy.Neurol. Sci. 2017; : 1-6https://doi.org/10.1007/s10072-017-3212-2
- Assessment of midbrain atrophy in patients with progressive supranuclear palsy with routine magnetic resonance imaging.Acta Neurol. Scand. 2007; 116: 37-42https://doi.org/10.1111/j.1600-0404.2006.00767.x
- Topography of the human corpus callosum revisited—Comprehensive fiber tractography using diffusion tensor magnetic resonance imaging.NeuroImage. 2006; 32: 989-994https://doi.org/10.1016/j.neuroimage.2006.05.044
- Alzheimer's disease and corticobasal degeneration presenting as corticobasal syndrome.Mov. Disord. 2009; 24: 1375-1379https://doi.org/10.1002/mds.22574
- Anatomical differences between CBS-corticobasal degeneration and CBS-Alzheimer's disease.Mov. Disord. 2010; 25: 1246-1252https://doi.org/10.1002/mds.23062
- Pathology and sensitivity of current clinical criteria in corticobasal syndrome.Mov. Disord. 2014; 29: 238-244https://doi.org/10.1002/mds.25746
- Cerebrospinal fluid {beta}-amyloid 42 and tau proteins as biomarkers of Alzheimer-type pathologic changes in the brain.Arch. Neurol. 2009; https://doi.org/10.1016/j.jalz.2010.05.534
- Tauopathies and synucleinopathies: do cerebrospinal fluid β-amyloid peptides reflect disease-specific pathogenesis?.J. Neural Transm. 2007; https://doi.org/10.1007/s00702-007-0629-4
- A panel of nine cerebrospinal fluid biomarkers may identify patients with atypical parkinsonian syndromes.J. Neurol. Neurosurg. Psychiatry. 2015; https://doi.org/10.1136/jnnp-2014-309562
- Accuracy of a panel of 5 cerebrospinal fluid biomarkers in the differential diagnosis of patients with dementia and/or parkinsonian disorders.Arch. Neurol. 2012; 69: 1445-1452https://doi.org/10.1001/archneurol.2012.1654
- Apolipoprotein e ε4 is a determinant for Alzheimer-type pathologic features in tauopathies, synucleinopathies, and frontotemporal degeneration.Arch. Neurol. 2004; https://doi.org/10.1001/archneur.61.10.1579
- Cerebrospinal fluid TAR DNA-binding protein 43 combined with tau proteins as a candidate biomarker for amyotrophic lateral sclerosis and frontotemporal dementia spectrum disorders.Dement. Geriatr. Cogn. Disord. 2017; 44: 144-152https://doi.org/10.1159/000478979
- Development and assessment of sensitive immuno-PCR assays for the quantification of cerebrospinal fluid three- and four-repeat tau isoforms in tauopathies.J. Neurochem. 2012; https://doi.org/10.1111/j.1471-4159.2012.07911.x
Article info
Publication history
Published online: January 29, 2019
Accepted:
January 28,
2019
Received in revised form:
January 23,
2019
Received:
August 30,
2018
Identification
Copyright
© 2019 Elsevier B.V. All rights reserved.
